Fresh Tracks Therapeutics, Inc. Share Price
Equities
FRTX
US10802T2042
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9101 USD | -1.14% | +1.09% | +3.53% |
15/03 | Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index | CI |
Sales 2022 | 6.94M 579M | Sales 2023 | 8.01M 668M | Capitalization | 5.25M 438M |
---|---|---|---|---|---|
Net income 2022 | -21M -1.75B | Net income 2023 | -5M -417M | EV / Sales 2022 | -0.59 x |
Net cash position 2022 | 8.63M 720M | Net cash position 2023 | 10.87M 906M | EV / Sales 2023 | -0.7 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.83
x | Employees | 4 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.4% |
1 day | -1.14% | ||
1 week | +1.09% | ||
Current month | +0.62% | ||
1 month | +1.12% | ||
3 months | -7.13% | ||
6 months | -0.11% | ||
Current year | +3.53% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 01/20/01 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 01/16/01 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.9101 | -1.14% | 795 |
25/24/25 | 0.9206 | -1.01% | 422 |
24/24/24 | 0.93 | +2.20% | 13,430 |
23/24/23 | 0.91 | 0.00% | 510 |
22/24/22 | 0.91 | +1.08% | 17,356 |
Delayed Quote OTC Markets, April 26, 2024 at 10:32 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
+3.53% | 5.44M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- FRTX Stock